I see no indication that CMS is changing requirements around cgm systems so as to allow Medtronic to have their systems covered without being held to the same established standards which Dexcom G5/G6 and the Abbott Freestyle Libre are currently held to.
Certainly if you have any links from CMS to the contrary, that would be very interesting to read.
CMS requires a cgm to be non-adjunctive in order to be eligible for coverage for Medicare. This means the FDA must have provided approval for dosing of insulin directly upon the cgm reading without the need for a fingerstick meter reading. This is not related to calibrations.
= = = =
Medtronic has a clinical trial listed as NCT03040414 which has been pushed back a few times (as shown online in the record of historical changes) and still is not reported as being in the enrollment stage. The clinical trial listing shows the estimated study start as March 30, 2019 with an estimated study completion date of June 29, 2020. This clinical trial was previously referring to the 690G however the name “690G” has now been removed in an update to the listing. It is possible this is still the study which Medtronic plans to use for their next pump and has decided to call their next pump the 780G rather than the 690G.
It is also possible that Medtronic has a different clinical trial that they will be using for the next model of their insulin pump. If anybody has a Clinical Trial ID number other than the one listed which appears to be intended for the next model pump from Medtronic, that would also be very interesting to read about.
In any event, Medtronic will have their earnings release and conference call next week on February 19th, 2019. At that time they will have a large amount of information released which undoubtedly would directly address many questions about specific product pipelines with timeframes.